1- **Surname:** Mohebali **Date of Birth:** 1959
First Name: Mehdi **Nationality:** Iranian

2- **Degree(s)**

2-1-General Doctorate Degree in Veterinary Medicine **(VMD)** University of Tehran (1977-1985).

2-2-Master of Public Health **(MPH)** from School of Public Health,Tehran University of Medical Sciences (1988).

3-3- **Ph.D** in Medical Parasitology and Mycology from the School of Public Health,Tehran University of Medical Sciences(1988-1991).

3- **Scientific position**

Full professor of Medical Parasitology and Mycology Department , School of Public Health,Tehran University of Medical Sciences from 2001.

4- **Address**

Poor-e-Sina Street,Tehran University of of Medical sciences, School of Public Health, Department of Medical Parasitology and Mycology ,leishmaniases laboratory. P.O.Box:١٤١٥٥ - ٦٤٤٦; Tel: (+9821) ٨٨٩٥١٤٠٠;

Fax: (+9821)88951392; E.mail: **mohebali@tums.ac.ir**; **mehdimohebali.tums@gmail.com**

5.Research background: Different aspects of cutaneous and visceral leishmaniasis

5- **No.of English papers Published from 2006-2020= 493 papers with 9648 citations.**

***H- index*=47**
***G- index*=68**

Member of 1% world scientists in medical sciences referring to ESI in 2018.

We are pleased to introduce Dr. Mehdi Mohebali, whose pioneering research and leadership in the study of *Leishmania* and leishmaniasis have significantly advanced our understanding of leishmaniasis. His work has been instrumental in global efforts to control and eliminate this important disease. Through innovative studies and extensive international partnerships, Dr. Mohebali has played a key role in

improving laboratory diagnosis and experimental treatment strategies and public health policies aimed at managing the disease worldwide.

Dr. Mohebali has been central to advancing knowledge on *Leishmania* parasites, which cause both cutaneous and visceral forms of leishmaniasis. His pioneering work on leishmanization—utilizing controlled exposure to live parasites for vaccination—has contributed to the development of safer and more effective preventive measures, offering new opportunities to tackle these diseases in endemic areas.

On the international stage, Dr. Mohebali has built essential collaborations with leading research institutions, health organizations, and countries affected by leishmaniasis. His efforts have helped standardize diagnostic techniques, enhance vaccine development, and share best practices for disease control, fostering stronger global cooperation in combating this neglected tropical disease.

Dr. Mohebali's expertise is widely recognized by major health organizations, including the World Health Organization (WHO), where he facilitates knowledge exchange and capacity building among professionals worldwide. His dedication to public health has also earned him numerous national awards, acknowledging his exceptional contributions to medical research and disease control within his home country. With an extensive portfolio of influential publications and a continued commitment to mentoring emerging scientists, Dr. Mohebali bridges the gap between laboratory and clinical researches, exemplifying outstanding leadership in the fight against leishmaniasis.

Five Top papers have been published during 2025:

1. Allahmoradi M. Mohebali M* . Mirjalali H. Adabi M. Firouzjaei Karder F. Rezayat S.M. Rahimi Foroushani A. Mousavi S.E. Kazemirad E. Nanofibrous patches for targeted therapy of cutaneous leishmaniasis caused by Leishmania major: a preclinical amphotericin B platform. Parasitology Research (2025) 124:160;1-20. https://doi.org/10.1007/s00436-025-08605-x.
2. Mohebali F. Aghabarari B* . Vaezi MR. Zarei Z. Hassanpour Gh.R. Alizadeh Z. Latifi AR. Mohebali M*.Biomacromolecule chitosan carrying meglumine antimoniate coated on a silver/polyurethane nanocomposite as a wound dressing: Therapeutic efficacy on cutaneous leishmaniasis caused by Leishmania major in BALB/c mice. International Journal of Biological Macromolecules.2025.307:1-12.141847. https://doi.org/10.1016/j.ijbiomac.2025.141847
3. Alizadeh Z.Mohebali M *. Aghabarari B*. Zarei Z. Hassanpour Gh.R. Eskandari SE. Mehdi Parsaei M. Jamshidi Sh. Rahimi Foroushani A. Keshavarz H. Akhoundi B.Heidari Z. Mohebali F. Yasini S.P. Hassanpour A. Formulation, in vitro evaluation and therapeutic effect of chitosan coated pluronic F127 micelles containing miltefosine for the treatment of visceral leishmaniasis in domestic dogs naturally infected by Leishmania infantum. Research in Veterinary Science 182 (2025) 105467.1-12. https://doi.org/10.1016/j.rvsc.2024.105467.
4. Mirabedini Z. Mohebali M*. Mirjalali H. Hajjaran H. Goudarzi F. Mohammad Rahimi. The expression profile of inflammatory microRNAs in Leishmania major infected human macrophages; mining the

effects of Leishmania RNA virus. BMC Microbiology. 2025. 25:187. 1-9. https://doi.org/10.1186/s12866-025-03901-z

5. Saberi M. Latifi AR. Golkar M. Fard-Esfahani P. Mohtasebi S. Teimouri A. Abbaszadeh Afshar Mj. Kazemirad E,* Mohebali M*. Contribution of epidermal growth factor (EGF) in the treatment of cutaneous leishmaniasis caused by Leishmania major in BALB/c mice. PLOS Neglected Tropical Diseases. 2025. 19(1): e0012765.https://doi.org/10.1371/ journal.pntd.0012765

****